Kolexia
Plante-Bordeneuve Violaine Neurologie
Plante-Bordeneuve Violaine
Neurologie
Hôpital Henri Mondor
Créteil, France
176 Activités
15 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Amyloïdose Neuropathies amyloïdes familiales Polyneuropathies Neuropathies amyloïdes Cardiomyopathies Amyloïdose familiale Neuropathies périphériques Défaillance cardiaque Cardiopathies

Collaborateurs

Voir plus
Damy Thibaud
Damy Thibaud
Hôpital Henri Mondor, Créteil, France
Lefaucheur Jean Pascal
Lefaucheur Jean Pascal
Hôpital Henri Mondor, Créteil, France
Adams David
Adams David
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Guendouz Soulef
Guendouz Soulef
Hôpital Henri Mondor, Créteil, France

Industries

Voir plus
A+A
10 collaboration(s)
Dernière en 2023
Akcea Therapeutics
5 collaboration(s)
Dernière en 2020
ICON CLINICAL RESEARCH SARL
3 collaboration(s)
Dernière en 2020
Pfizer
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Essai Clinique (Alnylam)   18 mars 2024
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Expert opinion on drug discovery   27 janvier 2024
Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
PloS one   19 janvier 2024
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran): A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
Essai Clinique (Alnylam)   05 décembre 2023
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP): An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)
Essai Clinique (Ionis Pharmaceuticals, Inc.)   17 novembre 2023
A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Orphanet journal of rare diseases   10 novembre 2023
PREVALENCE AND FEATURES OF INFLAMMATORY DEMYELINATING POLYNEUROPATHIES ASSOCIATED WITH BRENTUXIMAB-VEDOTIN THERAPY: A RETROSPECTIVE COHORT STUDY
2023 PNS Annual Meeting – Copenhagen, 17‐20 June 2023   09 octobre 2023
GENETIC MODIFIERS IN HEREDITARY AND ACQUIRED TTR AMYLOIDOSIS: UPDATE ON GENOME-WIDE ASSOCIATION STUDY
2023 PNS Annual Meeting – Copenhagen, 17‐20 June 2023   09 octobre 2023
Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association   01 septembre 2023
Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca.
Orphanet journal of rare diseases   31 août 2023